Physician profile
David M Dresner
NPI 1417955667
$6,551.87
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,392 · 2020: $424 · 2021: $1,343 · 2022: $1,537 · 2023: $1,793 · 2024: $62.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,830 · Education: $25.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,830.33 |
| Education | $25.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,617.37 | 2019-2023 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,052.66 | 2019-2024 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $886.93 | 2019-2023 | Entyvio, Gattex |
| Janssen Biotech, INC. | $838.92 | 2019-2023 | Stelara, Remicade, Simponi Aria |
| Pfizer INC. | $300.89 | 2019-2023 | |
| Gilead Sciences, INC. | $251.43 | 2019-2023 | |
| Genzyme Corporation | $148.25 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $133.86 | 2022-2023 | Dupixent |
| Merck Sharp & Dohme LLC | $119.95 | 2019-2023 | Dificid |
| Daiichi Sankyo INC. | $111.99 | 2019-2023 | Injectafer |
| Ironwood Pharmaceuticals, INC | $111.98 | 2019-2023 | Linzess |
| Qol Medical, LLC | $99.07 | 2019-2023 | Sucraid |
| Ardelyx, INC. | $83.23 | 2022-2023 | Ibsrela |
| Boston Scientific Corporation | $78.92 | 2022-2023 | Watchman Access System |
| Intercept Pharmaceuticals, INC. | $77.18 | 2021-2023 | Ocaliva |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $64.60 | 2021-2024 | Givlaari |
| Celgene Corporation | $64.18 | 2021-2023 | Zeposia |
| Evoke Pharma, INC. | $52.52 | 2020-2023 | Gimoti |
| Organon LLC | $51.35 | 2021-2023 | Renflexis |
| Amgen INC. | $47.99 | 2021-2022 | |
| Ucb, INC. | $37.08 | 2019-2020 | |
| Tersera Therapeutics LLC | $28.71 | 2023 | Xermelo, Zoladex |
| Pharmacosmos Therapeutics INC. | $27.57 | 2021 | |
| Celltrion USA INC. | $25.08 | 2023 | Yuflyma |
| Csl Behring | $24.68 | 2019-2021 | |
| Redhill Biopharma INC. | $23.20 | 2021-2022 | |
| Mylan Institutional INC. | $20.00 | 2023 | Hulio |
| Astrazeneca Pharmaceuticals LP | $18.98 | 2023 | Andexxa |
| Vivus LLC | $17.38 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.24 | 2023 | Cyltezo |
| Medtronic USA, INC. | $14.75 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.45 | 2023 | Voquezna |
| Novo Nordisk INC | $13.96 | 2023 | Wegovy |
| Fresenius Kabi USA, LLC | $13.51 | 2024 | Idacio |
| Sandoz INC. | $13.30 | 2022 | |
| Romark Laboratories, Lc | $12.77 | 2019 | |
| Medtronic, INC. | $12.77 | 2022 | |
| Shionogi INC | $12.44 | 2019 | |
| Shire North American Group INC | $11.73 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Dresner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.